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Abstract 
Background: Heart rate variability (HRV) is an objective, non‑invasive tool to assessing autonomic dysfunction in 
chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). People with CFS/ME tend to have lower HRV; how‑
ever, in the literature there are only a few previous studies (most of them inconclusive) on their association with 
illness‑related complaints. To address this issue, we assessed the value of different diurnal HRV parameters as potential 
biomarker in CFS/ME and also investigated the relationship between these HRV indices and self‑reported symptoms 
in individuals with CFS/ME.
Methods: In this case–control study, 45 female patients who met the 1994 CDC/Fukuda definition for CFS/ME and 
25 age‑ and gender‑matched healthy controls underwent HRV recording‑resting state tests. The intervals between 
consecutive heartbeats (RR) were continuously recorded over three 5‑min periods. Time‑ and frequency‑domain 
analyses were applied to estimate HRV variables. Demographic and clinical features, and self‑reported symptom 
measures were also recorded.
Results: CFS/ME patients showed significantly higher scores in all symptom questionnaires (p < 0.001), decreased RR 
intervals (p < 0.01), and decreased HRV time‑ and frequency‑domain parameters (p < 0.005), except for the LF/HF ratio 
than in the healthy controls. Overall, the correlation analysis reached significant associations between the question‑
naires scores and HRV time‑ and frequency‑domain measurements (p < 0.05). Furthermore, separate linear regression 
analyses showed significant relationships between self‑reported fatigue symptoms and mean RR (p = 0.005), RMSSD 
(p = 0.0268) and HFnu indices (p = 0.0067) in CFS/ME patients, but not in healthy controls.
Conclusions: Our findings suggest that ANS dysfunction presenting as increased sympathetic hyperactivity may 
contribute to fatigue severity in individuals with ME/CFS. Further studies comparing short‑ and long‑term HRV record‑
ing and self‑reported outcome measures with previous studies in larger CFS/ME cohorts are urgently warranted.
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Background
Chronic fatigue syndrome (CFS), also known as myal-
gic encephalomyelitis (ME) is a debilitating and com-
plex multisystem condition of unknown aetiology with 
high incapacitating potential due to severe and unex-
plained fatigue that cannot be alleviated by rest. Along 
with disabling fatigue, CFS/ME presents an array of 
core symptoms including autonomic dysfunction, unre-
freshing sleep, cognitive impairment (sometimes called 
also “brain fog”), post-exertional malaise, and muscle 
pain (or myalgias) [1].
In medical research, heart rate variability (HRV) 
analysis is an objective and non-invasive tool that may 
play an important role in describing autonomic dys-
function in CFS/ME research and clinical practice, in 
tracking the natural fluctuations of autonomic func-
tion across various time spans, and in predicting the 
patients’ prognosis. Assessment of autonomic dysfunc-
tion by HRV analysis is easy to perform and offers the 
important advantage that it can track dynamic changes 
of cardiac autonomic function within minutes. Recently 
developed time- and frequency-domain analyses fur-
ther enhance the ability of HRV analysis to track active 
changes in cardiovascular autonomic function. These 
analyses are likely to become part of future diagnostic 
criteria for CFS/ME and may serve as a surrogate end-
point marker in clinical trials [2, 3].
Previous studies have provided strong evidence for 
autonomic nervous system (ANS) involvement in 
individuals with CFS/ME, including perturbations in 
the structure and function of brain (reflected by fMRI 
testing) [4–11]. In brief, cerebral blood flow volume 
changes and reduced HRV may lead to greater exacer-
bation of ANS symptoms in individuals with CFS/ME. 
In the current study, we performed both time and fre-
quency domain HRV analyses to examine closely the 
relationship between the physiological parameters of 
HRV and patient-reported symptom measurements. 
Time-domain variables are statistical operations on 
R–R intervals that measure the dispersion of the indi-
vidual cardiac cycle length around their mean. Fre-
quency-domain parameters provide information on 
the different constituents (frequencies) of the heart 
rate signal and their relative intensity (power) [12]. 
There are some discrepancies in the literature about 
the behaviour of the HRV variables in CFS/ME indi-
viduals: Yamamoto et  al. [13], for example, reported 
lower time- and frequency-domain parameters during 
head-up tilt in CFS/ME patients compared with healthy 
controls, but no differences in the baseline supine posi-
tion. Yataco et al. [14] did not find differences either in 
the baseline supine state or in response to upright tilt. 
De Becker et  al. [15] found differences in frequency 
domain parameters after tilting, but not in the supine 
position; and Frith et al. [16] found changes only in fre-
quency domain variables measured at rest.
In this study we aimed: (1) to explore different diurnal 
HRV time and frequency domain parameters as potential 
biomarker in CFS/ME, and (2) to assess whether these 
HRV measures are associated with early self-reported 
symptoms in individuals with CFS/ME.
Methods
Participants’ characteristics
A prospective, cross-sectional, case–control cohort 
study of 45 consecutive females who met the 1994 CDC/
Fukuda definition for CFS/ME [17] were recruited 
from a single outpatient tertiary referral centre (CFS/
ME Unit, Vall d’Hebron University Hospital, Barcelona, 
Spain) from January 2014 through March 2015. Twenty-
five matched non-fatigued healthy controls were also 
included through word-of-mouth and advertisements 
from the local community. All participants were of Cau-
casian descent, from the same geographical area, and 
had a sedentary life style at the time of study. Exclusion 
criteria for the study were previous or current diagnosis 
of autoimmune illnesses, multiple sclerosis, psychosis, 
major depression, cardiovascular disorders, haematologi-
cal disorders, infectious diseases, sleep apnea or thyroid-
related illnesses, pregnancy or breast-feeding, smoking, 
hormone-related drugs, or any symptoms that might be 
confused with those of CFS/ME.
Setting and data collection
All eligible participants attended a first face-to-face inter-
view in which demographic and clinical characteristics 
were collected along with patient-reported outcome 
measures. They were asked about their fatigue sever-
ity using the Fatigue Impact Scale (FIS-40), their auto-
nomic dysfunction with both the abbreviated Composite 
Autonomic Symptom Score (COMPASS-31) and Neu-
rovegetative Complaints Questionnaire (NCQ), their 
sleep problems using the Pittsburgh Sleep Quality Index 
(PSQI), and anxiety and depression through the Hospi-
tal Anxiety and Depression Scale (HADS). After the first 
interview, participants were set dates for the following 
Keywords: Autonomic dysfunction, Chronic fatigue syndrome, Fatigue, Heart rate variability, Myalgic 
encephalomyelitis
Page 3 of 12Escorihuela et al. J Transl Med            (2020) 18:4 
additional HRV recording sessions. All records were 
done at the same location during working days.
Measures
Participants were asked to fill out validated self-reported 
outcome measures as symptom assessment tools. The 
following measures were used to evaluate all participants 
under the supervision of two trained investigators (JC-M 
and JA) who oversaw participant compliance.
Neurovegetative Complaints Questionnaire
The Neurovegetative Complaints Questionnaire (NCQ) 
was originally developed to measure neurovegetative, 
somatic and emotional complaints in post-concussive 
patients. The original questionnaire consisted of 28 items 
concerning headaches, problems with falling asleep, rest-
lessness, chest pain, indigestion, slowness of working, 
sensitivity to light, effort, flushing, concentration, dysp-
noea, preference for being left alone, tiredness, fainting, 
heart palpitations, noise, difficulty with doing two tasks 
simultaneously, preference for working at one’s own pace, 
dizziness, depression, wet hands, crying spells, altered 
libido, irritability, lack of initiative, awakening at night, 
defeatism, and not being appreciated by others. Par-
ticipants had to indicate the frequency of occurrence of 
these symptoms on a 4-point Likert scale (1 = no, never; 
2 = yes, sometimes; 3 = yes, regularly, and 4 = yes, often). 
Higher scores indicated more autonomic complaints [18].
Fatigue Index Scale
The Fatigue Impact Scale (FIS-40) is a 40-item question-
naire designed to assess fatigue symptoms as part of an 
underlying chronic condition. It includes three domains 
reflecting the perceived feeling of fatigue: physical (10 
items), cognitive (10 items) and psychosocial functions 
(20 items). Each item is scored from 0 (no fatigue) to 4 
(severe fatigue). The overall score is calculated by adding 
together the responses to the 40 questions (ranging from 
0 to 160). Higher scores indicate more functional limita-
tions due to fatigue [19].
Composite Autonomic Symptom Score
For measuring autonomic dysfunction, all participants 
were screened the Composite Autonomic Symptom 
Score (COMPASS-31), a 31-item questionnaire designed 
to evaluate the frequency and severity of autonomic 
function symptoms, grouped in six domains: orthostatic 
intolerance (4 items), vasomotor (3 items), secretomotor 
(4 items), gastrointestinal (12 items), bladder (3 items) 
and pupillomotor systems (5 items). Added together, the 
six domain scores provide a total COMPASS-31 score 
ranging from 0 to 100. Higher scores indicate more 
severe autonomic complaints [20].
Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality Index (PSQI) is a 19-item 
self-administrated questionnaire commonly used to 
assess sleep disturbances over a 1-month interval. Scores 
are acquired on each of seven domains of sleep quality: 
subjective sleep quality, sleep latency, sleep duration, 
habitual sleep efficiency, sleep disturbances, use of sleep-
ing medication, and daytime dysfunction. Each domain is 
scored from 0 to 3 (0 = no problems and 3 = severe prob-
lems). The overall PSQI score ranges from 0 to 21 points, 
with scores of ≥ 5 indicating poorer sleep quality [21].
Hospital Anxiety and Depression Scale
To assess anxiety and depression symptoms the Hospital 
Anxiety and Depression Scale (HADS) was used; a vali-
dated 14 item self-reported measure (seven items associ-
ated with anxiety symptoms and seven with depression) 
over the last week. Each item is scored on a 4-point Lik-
ert scale (e.g., 0 = as much as I always do; 1 = not quite 
so much; 2 = definitely not so much; and 3 = not at all) 
giving maximum subscale scores of 21 for depression 
and anxiety, respectively. Scores of 0–7 are interpreted 
as normal; scores of 8–10 reflect mild symptoms, 11–14 
moderate, and 15–21 severe for either anxiety or depres-
sion. The global HADS score ranges from 0 (no anxiety/
depression) to 42 (severe anxiety/depression symptoms) 
[22].
Heart rate variability analysis
Heart rate variability was assessed between 3:00  pm 
and 6:00 pm in a semi-dark room maintained at a tem-
perature between 20 and 24  °C during weekdays. At 
the start of each test session, all subjects were asked 
to abstain from alcoholic and caffeinated beverages, 
cigarette smoking, cardioactive medications and heavy 
exercise (physical/mental activity) for at least 48  h 
prior to testing, as their actions might alter their auto-
nomic function. After 5  min of rest lying down, par-
ticipants were asked to remain in supine position and 
still without speaking or making any movements, and 
HRV data were recorded continuously for 5  min of 
natural breathing. Participant’s session ratings of con-
tinuous heart rate (RR or beat-to-beat cardiac intervals) 
were collected and analysed with the  FitLab® system 
(HealthSportLab.com, Barcelona, Spain); an application 
that runs on a mobile device (iOS, Apple) connected via 
Bluetooth (BTv4) with a cardiac chest band (Polar Elec-
tro Oy, Kempele, Finland) and connected via wireless 
to a remote server. The system allows performance of 
individual HRV recordings in each session and checks 
data quality in real time. All participants performed the 
Page 4 of 12Escorihuela et al. J Transl Med            (2020) 18:4 
three 5-min HRV tests at rest in the supine position. 
The intervals between consecutive heartbeats (R–R) 
were continuously monitored over three 5-min periods 
on different days.
Heart rate variability analysis was performed for RR 
intervals in 5  min periods using the  FitLab® software, 
following the recommendations of the Task Force of the 
European Society of Cardiology and the North American 
Society of Pacing and Electrophysiology [23].
For the time domain analysis, the mean of RR inter-
vals (mean RR), the standard deviation of all RR intervals 
(SDRR), the root mean square of differences (RMSSD) of 
successive RR intervals and the mean number of times 
an hour in which the change in successive normal sinus 
(RR) intervals exceeds 50 mseg (pNN50) were calcu-
lated. For frequency domain analysis, all RR series were 
resampled at 3 Hz using a cubic spline prior to the HRV 
analysis. Power–frequency analysis of the 5-min record-
ings was performed sequentially with a fast Fourier trans-
form based on a non-parametric algorithm with a Welsh 
window after the ectopic-free data were detrended and 
resampled with a cubic spline interpolation [24]. The 
power in the very low frequency (VLF) band (0.0033–
0.04  Hz), the low frequency (LF) band (0.04–0.15  Hz) 
and the high frequency (HF) band (0.15–0.40  Hz) were 
calculated from each 5-min spectrum by integrating the 
spectral power density in the respective frequency bands. 
Additional calculations included the LF/HF ratio, as well 
as the normalized LF and HF values (LFnu and HFnu, 
respectively). For the final analysis of each variable, the 
values obtained in the three independent recordings were 
averaged.
Statistical analysis
Data were analysed using the IBM SPSS Statistics Pack-
age for Mac OS (version 23.0, SPSS Inc., Chicago, IL). 
Descriptive statistics and outcome measures for each 
item were shown as mean ± standard error of the mean. 
Calculation of HRV parameters was carried out with 
 FitLab® software (HealthSportLab.com, Barcelona, 
Spain) and MATLAB environment. Differences between 
unrelated groups were assessed with the Student’s t-test 
for independent samples, and non-parametric Mann–
Whitney U test when appropriate. Pearson correlation 
analyses were used to test bivariate associations between 
questionnaires scores and HRV indices or between ques-
tionnaires scores themselves. Finally, to further evaluate 
the relative relationship between the most significant 
HRV parameters and patient-reported fatigue severity, 
we performed separate regression analyses in CFS/ME 
patients and healthy controls. The significance threshold 
was set at p < 0.05.
Results
Demographic and clinical characteristics of participants
Table  1 presents the demographic, clinical character-
istics and baseline self-reported measures among the 
participants. There were no significant differences in 
age, BMI or SBP between ill and healthy controls. Heart 
rate and diastolic blood pressure were higher among 
ill than healthy controls (p = 0.002 and p = 0.022, 
respectively).
Table 1 Demographic and  clinical characteristics 
of participants at time of recruitment
Baseline self-reported measures scores (global and subscales) of symptoms, as 
explained in “Methods” section. Data are shown as mean ± SEM for each item
a Data were analyzed using Student’s t test for independent samples, and the 




CFS/ME (n = 45) p-valuea
Age (years) 44.96 ± 1.30 46.41 ± 0.84 N.S.
BMI (kg/m2) 23.77 ± 0.61 24.59 ± 0.69 N.S.
SBP (mmHg) 115.2 ± 2.15 121.2 ± 1.99 0.057
DBP (mmHg) 74.45 ± 1.56 79.56 ± 1.38 0.022
HR (bpm) 67.71 ± 1.93 74.72 ± 1.21 0.002
NCQ 0.40 ± 0.15 10.11 ± 0.28 < 0.001
FIS‑40
 Global score (0–160) 17.12 ± 3.25 140.9 ± 1.79 < 0.001
  Physical 4.60 ± 0.94 36.95 ± 0.39 < 0.001
  Cognitive 4.48 ± 1.03 35.73 ± 0.66 < 0.001
  Psychosocial 8.04 ± 1.46 68.27 ± 1.04 < 0.001
COMPASS‑31
 Global score (0–100) 27.31 ± 2.42 80.10 ± 2.91 < 0.001
  Orthostatic intolerance 2.52 ± 0.25 7.45 ± 0.31 < 0.001
  Vasomotor 0.48 ± 0.21 1.93 ± 0.24 < 0.001
  Secretomotor 0.76 ± 0.18 4.73 ± 0.18 < 0.001
  Gastrointestinal 5.60 ± 0.74 13.45 ± 0.68 < 0.001
  Bladder 0.32 ± 0.11 3.48 ± 0.32 < 0.001
  Pupillomotor 2.96 ± 0.46 10.32 ± 0.55 < 0.001
PSQI
 Global score (0–21) 4.52 ± 0.63 15.05 ± 0.57 < 0.001
  Subjective sleep quality 0.56 ± 0.12 2.23 ± 0.14 < 0.001
  Sleep latency 0.72 ± 0.17 1.89 ± 0.16 < 0.001
  Sleep duration 0.92 ± 0.17 2.05 ± 0.13 < 0.001
  Habitual sleep efficiency 0.56 ± 0.22 1.95 ± 0.17 < 0.001
  Sleep disturbances 1.04 ± 0.07 2.27 ± 0.13 < 0.001
  Sleeping medication 0.28 ± 0.15 2.11 ± 0.19 < 0.001
  Daytime dysfunction 0.44 ± 0.12 2.55 ± 0.11 < 0.001
HADS
 Global score (0–42) 5.15 ± 0.70 26.68 ± 1.41 < 0.001
  Anxiety 3.96 ± 0.41 13.73 ± 0.73 < 0.001
  Depression 1.16 ± 0.29 12.95 ± 0.68 < 0.001
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Self-reported measures
The NCQ scores and the physical, cognitive, psychoso-
cial domains and global FIS-40 scores were an average 
of eight times higher than those reported by the healthy 
controls (p < 0.001; Table  1). The higher scores on these 
measures were consistent with the CFS/ME diagnosis. 
Regarding the autonomic symptoms self-reported in 
the COMPASS-31 questionnaire, the CFS/ME patients 
reported increases in orthostatic intolerance, vasomo-
tor, secretomotor, gastrointestinal, bladder, pupillomo-
tor dysfunction (all p < 0.001) and overall COMPASS-31 
score (p < 0.001) compared with the control subjects 
(Table  1). These results are also consistent with an 
increased number of autonomic symptoms reported in 
the NCQ (Table 1).
Regarding the patient-reported sleep symptoms in the 
PSQI questionnaire, the CFS/ME patients had higher 
scores for sleep quality, sleep latency, sleep duration, and 
sleep efficiency than controls (all p < 0.001; Table 1). CFS/
ME patients also reported increased sleep disturbances, 
greater use of sleep medication and increased daytime 
dysfunction (all p < 0.001; Table  1), and their total PSQI 
score was three times higher than in controls (p < 0.001, 
Table  1). CFS/ME patients reported higher scores of 
anxiety and depression on the HADS questionnaire (a 
mean of 10–11 points more) than controls (p < 0.001, 
Table 1).
Heart rate variability indices
Heart rate variability analysis showed significantly 
decreased values in CFS/ME patients compared with 
healthy controls for the time domain parameters: mean 
RR (Fig. 1a, p = 0.009), SDNN (Fig. 1b, p < 0.001), RMSSD 
(Fig.  1c, p < 0.001) and pNN50 (Fig.  1d, p < 0.001). HRV 
analysis for the frequency domain revealed significantly 
lower values for the parameters (LF, Fig.  2a, p = 0.011; 
HF, Fig. 2b, p < 0.001; HFnu Fig. 2c, p = 0.001), and higher 
LF/HF index (Fig. 2d, p = 0.014) in CFS/ME patients than 
in healthy controls.
Correlation between clinical measures and HRV 
parameters
Table  2 displays the correlation analysis between self-
reported symptoms and HRV domain indices, showing 
a negative association between the global FIS-40 score 
and the subscales with all HRV domain indices (p < 0.01), 
except for the LF/HF ratio with which the association 
was positive (p < 0.05). Regarding COMPASS-31, the 
Fig. 1 Comparison of the HRV time‑domain parameters among the participants. Values are shown as mean ± SEM of a mean of RR intervals (mean 
RR), b standard deviation of all R–R intervals (SDNN), c root mean square of successive RR intervals differences (RMSSD), and d the mean number 
of times in an hour in which the change in successive normal sinus R–R intervals exceeds 50 ms (pNN50). Significance level is indicated above the 
horizontal line in each chart
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domains for orthostatic intolerance, secretomotor and 
total score correlated negatively with all HRV indices 
(p < 0.01), except with LF/HF with which the correlation 
was positive (p < 0.05). The gastrointestinal domain cor-
related negatively with all HRV indices (p < 0.01), except 
for the LF/HF ratio which correlated positively (p < 0.05). 
The pupillomotor domain showed a negative correlation 
with all indices except for LF/HF index. The vasomotor 
domain presented a significant negative correlation with 
mean RR (p < 0.05); and the bladder item correlated nega-
tively with HFnu (p < 0.05).
The HADS-depression domain showed a negative cor-
relation with all HRV indices (p < 0.01), and a positive 
correlation with LF/HF ratio (p < 0.05). Finally, HADS-
anxiety domain showed a negative correlation (p < 0.05), 
but no correlation with LF/HF index.
On the PSQI questionnaire, sleep quality showed a 
negative correlation with the four indices of the HRV 
time domain analysis (p < 0.05), but only with the HF fre-
quency domain parameter (p < 0.05). Sleep latency did 
not correlate with any HRV parameter. Sleep duration 
showed a negative correlation with the HRV time domain 
parameters (SDNN, RMSSD and pNN50; all p < 0.05), 
but only a negative correlation with HF for the frequency 
domain (p < 0.01). Habitual sleep efficiency correlated 
significantly negatively with all indices (p < 0.05), except 
with mean RR (no significant correlation), and showed 
a positive correlation with LF/HF index (p < 0.05). Sleep 
disturbances correlated negatively with all indices 
(p < 0.05) except for LF (no significant correlation), and 
positively with LF/HF (p < 0.05). Sleep medication corre-
lated negatively with all indices (p < 0.05) except for LF/
FH and HFnu (no significant correlation). Daytime dys-
function and overall PSQI score correlated negatively 
with all HRV parameters (p < 0.01); except for a signifi-
cant positive correlation with LF/HF index (p < 0.01).
As showed in Table 2, all correlations were negative for 
the outcomes measures scores, except for LF/HF ratio, 
thus indicating that lower HRV domain values were asso-
ciated with higher self-reported measure scores. How-
ever, a higher LF/HF index was associated with higher 
clinical symptom scores.
Interestingly, a closer look shows that FIS-40, HADS-
depression, overall PSQI and NCQ questionnaires had 
indices lower than − 0.40 and significances greater than 
0.01. In more in detail, the FIS-40 scores had correla-
tion indices below − 0.423 with all HRV time-domain 
parameters (mean RR, SDNN, RMSSD and pNN50), 
and with the HF and HFnu frequency-domain param-
eters, thus suggesting a robust and consistent associa-
tion between fatigue symptoms and these HRV domain 
parameters. HADS-depression had a correlation 
Fig. 2 Comparison of the HRV frequency‑domain measures in the study participants. Values are shown as mean ± SEM of a absolute power of the 
low frequency band (LF), b absolute power of the high frequency band (HF), c normalized HF value (HFnu) and d ratio of LF‑to‑HF power (LF/HF). 
Significance level is indicated above the horizontal line in each chart
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index below − 0.407 with SDNN, RMSSD and pNN50 
time-domain parameters, and with HFnu index of the 
frequency domain. Finally, overall PSQI had a nega-
tive correlation with SDNN and RMSSD time domain 
(r = − 0.407 and r = − 0.409, respectively) but did not 
correlate with any frequency domain parameters.
Finally, the simple linear regression analyses revealed 
clear differences among the study participants, since 
CFS/ME patients showed significant relationship 
between fatigue severity as measured by the FIS-40 
and HRV domain parameters such as mean RR (Fig. 3a, 
r = − 0.056, p = 0.005), RMSSD (Fig.  3b, r = − 0.055, 
p = 0.027) and HFnu (Fig.  3c, r = − 0.365, p = 0.007). 
No such associations were found for each HRV domain 
in healthy controls.
Table  3 shows Pearson’s correlations between global 
scorings of self-reported questionnaires as PSQI, 
NCQ, COMPASS-31, and HADS. All correlations 
were positive, highly significant and higher than 0.71 
(p < 0.01). Most correlation coefficients (r-values) were 
higher than 0.8. The r-value between FIS-40 and NCQ 
was 0.942 (Table 3).
Discussion
This study, designed to identify HRV analysis-derived 
putative indices associated with self-reported measures 
in CFS/ME, provides the first evidence of a significant 
relationship between HRV and fatigue severity in this 
condition. The findings of this study showed a high asso-
ciation between the questionnaires scores themselves, 
indicating a close relationship among all the symptoms. A 
second finding was that all HRV indices (from frequency 
and temporal domain analyses), except for the LF/HF 
ratio, were negatively correlated with the self-reported 
questionnaire scores in both ill and control groups. This 
indicates that, as expected, low HRV is associated with 
high scores for fatigue, autonomic dysfunction, sleep 
Table 2 Pearson correlation coefficients (r) between  HRV parameters (both time- and  frequency-domains) and  self-
reported measures in the sample
Significance: *p < 0.05; **p < 0.01
Mean RR SDRR RMSSD pNN50 LF HF LF/HF HFnu
PSQI
 Sleep quality − .244* − .302* − .302* − .279* − .226 − .275* .174 − .203
 Sleep latency − .047 − .190 − .190 − .161 − .124 − .170 .188 − .152
 Sleep duration − .223 − .290* − .295* − .251* − .180 − .320** .213 − .216
 Habitual sleep efficiency − .182 − .288* − .306* − .285* − .251* − .308* .284* − .249*
 Sleep disturbances − .301* − 286* − .323** − .291* − .226 − .275* .303* − .283*
 Sleeping medication − .261* − .407** − .385** − .380** − .285* − .322** .130 − .190
 Daytime dysfunction − .297* − .394** − .394** − .385** − .277* − .332** .367** − .403**
 Global score − .285* − .405** − .409** − .381** − .295* − .373** .302* − .312**
NCQ − .332** − .378** − .409** − .399** − .250* − .358** .341** − .409**
FIS‑40
 Physical − .438** − .442** − .494** − .498** –.326** − .435** .309* − .423**
 Cognitive − .440** − .464** − .507** − .512** –.322** − .451** .360** − .476**
 Psychosocial − .439** − .462** − .501** − .502** –.337 − .438** .324** − .431**
 Global score − .442** − .460** − .504** − .507** –.332 − .443** .332** − .443**
HADS
 Anxiety − .334** − .347** − .379** − .377** − .273* − .339** .137 − .283*
 Depression − .371** − .407** − .446** − .435** − .249* − .377** .308* − .449**
 Global score − .367** − .390** − .429** − .422** − .271* − .372** .236 − .384**
COMPASS‑31
 Orthostatic intolerance − .367** − .383** − .390** − .362** − .283* − .323** .276* − .314**
 Vasomotor − .293* − .155 − .170 − .194 − .095 − .092 .060 − .186
 Secretomotor − .330** − .379** − .395** − .396** − .291* − .319** .271* − .333**
 Gastrointestinal − .315** − .278* − .342** − .360** − .203 − .251* .301* − .356**
 Bladder − .183 − .181 − .239 − .229 − .133 − .225 .219 − .301*
 Pupillomotor − .322** − .319** − .347** − .353** − .189 − 294* .192 − .289*
 Global score − .368** − .359** − .400** − .397** − .261* − .317** .307* − .370**
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quality, anxiety and depression symptoms. Finally, this 
study reveals a relationship of two HRV indices (RMSSD 
and HFnu) with fatigue symptoms; that is, low values of 
RMSSD (obtained from time domain HRV analysis) and 
low values of HFnu (obtained from frequency domain 
analysis) are specifically associated with high fatigue 
symptoms (as assessed by overall FIS-40 score) in the 
CFS/ME patients, but not in healthy controls. As this 
relationship did not appear between other HRV variables 
and other self-reported measures scores, we believe that 
this is the first evidence of an association between HRV 
changes and outcome measures in CFS/ME.
This study shows that HRV analysis is a clinically useful 
non-invasive tool for predicting fatigue severity in CFS/
ME. Both the time- and frequency-domain indices were 
closely related to self-reported autonomic dysfunction, 
sleep quality, and anxiety and depression in clinical out-
patients. CFS/ME patients had lower mean RR, SDNN, 
RMSSD and pNN50 than healthy controls, and lower LF, 
HF and HFnu but higher LF/HF. Even though the first set 
of these HRV parameters were obtained from the time 
domain analysis and the second set from the frequency 
domain analysis, they all indicate that CFS/ME patients 
showed decreased HRV associated with autonomic 
dysfunction, sleep quality and anxiety/depression symp-
toms. This is an important finding because the two types 
of variables point in the same direction, thus adding 
robustness to the results.
This is the first study to show this consistency between 
the different HRV indices. To some extent, our results 
corroborate those of previous studies. Yamamoto et  al. 
[13] reported lower mean RR, but not SDNN, in CFS/
ME patients than in matched healthy controls in baseline 
supine position. In contrast, Yataco et  al. [14] had pre-
viously reported no differences in LF, HF and LF/HF in 
baseline supine position between CFS/ME patients and 
healthy controls.
During sleep, Boneva et  al. [25] found shorter mean 
RR and reduced LF coupled with higher nor-epineph-
rine levels and lower aldosterone levels in plasma. The 
authors interpreted this as a state of sympathetic ANS 
predominance and neuroendocrine disturbances. Moni-
toring HR during nocturnal sleep in CFS/ME, Rahman 
et al. [26] found decreased RMSSD, HF and LF/HF ratio 
in CFS/ME patients compared to those healthy controls. 
This result is in line with Meeus et  al. review [27] who 
concluded that HRV was only reduced during sleep in 
ME/CFS.
Lewis et  al. [6] used frequency domain analysis to 
investigate the differences in autonomic dysfunction 
between two CFS/ME subgroups, POTS vs. non-POTS. 
Interestingly, they found lower LF, HF and VLF in the 
POTS cases. The authors did not include HRV time 
domain parameters, and they proposed these frequency 
indices as candidate biomarkers for distinguishing 
between these two CFS/ME phenotypes.
A relevant feature of the procedure used in the cur-
rent study for recording the RR intervals is the use of 
Fig. 3 Correlation analysis between fatigue severity perception and HRV indices among the participants. Total FIS‑40 score significantly correlated 
with a the mean RR, b the RMSSD, and c the HFnu among CFS/ME patients (black squares, upper regression lines) but not for those healthy controls 
(white circles, bottom regression lines). Significant correlations were found between HRV indices and presence of perceived fatigue among CFS/ME 
individuals (p < 0.01 for mean RR and HFnu, and p < 0.05 for RMSSD), but not in healthy controls
Table 3 Pearson correlations between  measures assessed 
in the sample
Significance: **p < 0.001
Measures NCQ FIS-40 HADS COMPASS-31
PSQI .824** .813** .729** .816**
NCQ .942** .796** .852**
FIS‑40 .843** .839**
HADS .796**
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5-min records obtained on 3 different days (similar 
time schedule, 15–18  h) from each participant. The 
three values of each variable were averaged and used 
for the final analysis. It is likely that this method con-
ferred robustness on the measure and, in consequence, 
led to a more reliable HRV value, less contaminated by 
everyday variables such as lifestyle habits, food, activ-
ity, sleep problem, medication, and so on.
In a recent study from our group exploring abnor-
malities of circadian rhythm and dysautonomia in CFS/
ME, we found changes in the chronotype and symp-
tom patterns in these patients compared with healthy 
controls. The findings of that study also showed a dif-
ference of almost 10 points in self-reported autonomic 
symptoms [28]. Using the COMPASS, which included 
73 questions that assess autonomic dysfunction symp-
toms in CFS/ME, Newton et al. [29] concluded that an 
overall COMPASS cut-off score ≥ 32.5 was considered 
as a useful diagnostic criterion for ANS dysfunction in 
individuals with CFS/ME. In the current study, CFS/
ME patients reported increased orthostatic intolerance, 
and higher scores of vasomotor, secretomotor, gastro-
intestinal, bladder, pupillomotor symptoms and total 
COMPASS scores than healthy controls, in line with 
previous results reported by our group [28] and others 
[30].
The development of telemetric devices capable of 
detecting and capturing R–R interval signals, together 
with the applications that facilitate the analysis and pro-
vide the calculation of HRV indices, may facilitate the 
use of these signals as biomarker in research and clini-
cal practice. This study breaks new ground in the use of 
mHealth technology for the real-time analysis of cardiac 
variability in CFS/ME in a controlled situation. For exam-
ple, mHealth has been defined as the use of mobile com-
puting and communication technologies in healthcare 
and public health [31, 32]. The improvement in the speed 
of the processors, the smaller and longer-lasting batter-
ies, the greater memory capacity and very precise built-
in sensors enables more accurate monitoring of health 
parameters in real time and in natural situations [33].
Heart rate variability is considered an index of car-
diac autonomic modulation. In the frequency domain, 
vagal (parasympathetic) activity is the major contribu-
tor to HF variability, whereas both vagal and sympathetic 
activity contributes to LF variability. The LF/HF ratio is 
considered an index of sympathovagal balance. For time 
domain indices, vagal (parasympathetic) activity is the 
main contributor to pNN50 and RMSSD, whereas SDNN 
is a measure of total variability, analogous to the total 
power index in the frequency domain [24]. Autonomic 
function in CFS/ME shows sympathetic hyperactivity 
and parasympathetic hypoactivity and this autonomic 
imbalance might reflect an alteration of the central con-
trol pathomechanisms.
Studying parasympathetic activity by using HF power 
in the frequency domain method and RMSSD in the 
HRV time domain method, previous studies have shown 
that the HF component changes after electrical vagal 
stimulation, muscarinic receptor blockade, and vagotomy 
[24]. We found decreased mean RR, SDNN, RMSSD and 
pNN50 in CFS/ME patients compared with healthy con-
trols in the HRV time domain analysis of RR intervals, 
and the frequency domain analysis revealed decreased 
LF and HF, and HFnu and increased LF/HF index in CFS/
ME patients. This concurrence in these HRV indices from 
different domains had not been previously reported.
The robust association between fatigue symptoms, anx-
iety-depression and HRV indices also deserves mention. 
All scores of fatigue symptoms (physical, cognitive, psy-
chosocial and overall) correlated significantly and nega-
tively with all HRV indices, except for the LF/HF ratio, 
which showed a positive correlation. This indicates that 
increased fatigue coincides clearly with a reduced varia-
tion in the time interval between consecutive heartbeats. 
Anxiety and depression scores were also negatively and 
robustly associated with time domain HRV indices and 
with the HF index of the frequency domain, suggesting 
that anxiety and depression symptoms were associated 
with decreased HRV. All PSQI domains except sleep 
latency were negatively and robustly associated with the 
main HRV indices, including SDRR, RMSSD, pNN50 
and HF. This result is consistent with those of a previous 
study reporting lower nocturnal RMSSD and HF in CFS/
ME patients than in healthy controls [26]. In the current 
study, sleep efficiency, disturbances, sleeping medication 
and total scores were also associated with HFnu. Inter-
estingly, the correlations of HF and HFnu with the ques-
tionnaires scores were stronger than those of the LF and 
LF/HF indices. Overall, the significance of the HF and 
HFnu when present was greater than that of LF or LF/HF 
in all the correlations analysed, suggesting that HF and 
or HFnu may be more specific correlates of fatigue and 
comorbid health conditions than LF or LF/HF.
Regarding the COMPASS-31 results, four of the six 
domains (orthostatic intolerance, secretomotor, gastroin-
testinal, and pupillomotor) as well as the total score were 
associated with decreased HRV time domain and HF and 
HFnu parameters, which again corroborates the specific-
ity of those measures as biomarker that correlate with 
fatigue and comorbid conditions. We stress that orthos-
tatic intolerance, secretomotor and total scores were also 
associated with LF and the LF/HF ratio, but with a lower 
degree of significance than the other parameters men-
tioned above. Vasomotor and bladder domains were not 
associated with HRV, thus indicating certain specificity 
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in the association between the autonomic dysfunction 
scored by COMPASS-31 and HRV domain parameters. 
With the exception of the LF/HF ratio, a significant nega-
tive association was found between all the HRV param-
eters and symptoms of sleep disturbances, anxiety/
depression, autonomic dysfunction and, most signifi-
cantly, the fatigue scores. Thus, low values for the HRV 
indices were associated with high scores of the clinical 
symptoms.
Finally, the results showed a robust relationship 
between the self-reported measure score of fatigue 
assessed by FIS-40 scale and mean RR, RMSSD and 
HFnu HRV indices in CFS/ME patients, but not in 
healthy controls. Interestingly, HF domain together with 
mood status (assessed by the Profile of Mood Status) and 
blood biomarkers (such as serum dehydroepiandroster-
one sulfate levels, cortisol and TNF-α), HF improved in 
CFS/ME patients after a session of isometric yoga [34]. 
These changes may be related to a short-term fatigue-
relieving effect of sitting isometric yoga and the ensuing 
increase in vagal nerve functioning observed due to the 
reduction of the heart rate and the increase in high fre-
quency power. These results indicate the importance of 
the physiological parameters involved in the R–R vari-
ability, and of the assessment of fatigue severity status in 
individuals with CFS/ME.
Strengths and limitations
We believe that this study is unique for several reasons: 
(1) the sample size is adequate in a study involving CFS/
ME patients; (2) the reproducibility of HRV recordings 
and their technical quality were satisfactory: the use of 
the same location (medical lab), the same timing in the 
day and the week, the same device and the recordings of 
HRV were routinely performed by the same researcher; 
(3) the assessment of the ‘fatigue status’ and other core 
symptoms was based on patient-reported questionnaires 
that have been widely validated in the Spanish CFS/ME 
population and on an a priori threshold independent of 
HRV analysis; (4) from a practical point of view, we con-
sider that the current study will help to demonstrate the 
relevance of HRV time- and frequency-domain analyses 
for the quantification and monitoring of fatigue severity 
and its clinical impacts in CFS/ME. However, this study 
has several limitations that need to be addressed: (1) the 
study has a cross-sectional design and the sample size 
is relatively small; however, there is sufficient evidence 
to suggest a close relationship between ANS dysfunc-
tion (assessed by HRV analysis) and most (if not all) of 
the multisystem symptoms in CFS/ME. The primary 
cause of sympathetic dysfunction in ME/CFS remains 
to be defined. Therefore, longitudinal large-scale stud-
ies are now warranted to elucidate the HRV changes in 
people with CFS/ME and also assess the natural course of 
cardiac autonomic dysfunction, taking advantage of the 
capabilities offered by mHealth technology; (2) we did 
not use a ‘gold standard’ for the HRV measurements (i.e. 
24-h Holter ECG recorders); however, the  FitLab® system 
using the new mobile telemetric devices has proven to be 
an accurate and valid method for HRV measurements; 
(3) we did not include men with CFS/ME; this is an 
area we are currently exploring; (4) Short-term (5-min) 
HRV analysis was performed only for time- and spectral 
domains; perhaps other complex approaches for analys-
ing long-term HRV over the entire 24  h (e.g., approxi-
mate and sample entropy, detrended fluctuation analysis, 
long-term exposure, non-linear vs. linear dynamic meth-
ods, and so on) may provide valuable additional infor-
mation in relation to the prediction of fatigue status in 
individuals with CFS/ME.
Conclusions
This is the first study to investigate the relationship 
between HRV domain indices and patient-reported 
measures in individuals with CFS/ME. Our findings show 
that HRV analysis using mHealth technology is an objec-
tive, non-invasive tool that can be useful for clinical use 
to predict fatigue severity, which may therefore be part 
of the pathogenesis in CFS/ME, since both the time- and 
frequency-domain indices were closely associated with 
ANS dysfunction in this condition. This study provides a 
rationale for future longitudinal studies in larger CFS/ME 
cohorts, including men, would be of great help to assess 
the impact of the HRV measurement using mHealth tech 
and fatigue severity (i.e. HR monitoring to prevent post-
exertional malaise) both at baseline and after an exercise 
challenge (consecutive 2-day CPET) in patients with 
CFS/ME. Studies of this kind are also urgently needed 
to understand the pathophysiologic mechanisms due to 
neurohormonal imbalance, especially related with HPA 
axis and ANS dysfunction in the physical functioning and 
health-related well-being in people with CFS/ME.
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